SSB launches two single-use Sartocon loop assemblies with integrated polyethersulfone membrane
Assemblies save up to 60% on processing time and offer a safe approach to ultrafiltration of biologics and vaccines.
Sartorius Stedim Biotech (SSB) has announced its polyethersulfone membrane (PESU) is now integrated into two new, sterile Sartocon benchtop and production-scale filtration assemblies. Using these assemblies guarantees rapid and safe ultrafiltration of biologics and vaccines. Due to the fully enclosed design, the Sartocon assemblies are ideal for safely purifying vaccines and recombinant proteins, as well as monoclonal antibody manufacturing. This makes them suitable for use in cGMP environments for process development, clinical trials and small-scale production batches.
The new single-use Sartocon Self-contained Filter Loop Assembly has been developed for use with SSB’s unique control unit, the FlexAct UD. While the Sartocon Slice Self-contained Bag Loop Assembly has been designed for SSB’s benchtop crossflow system SARTOFLOW Alpha plus SU. Both assemblies are supplied gamma sterilized and ready to use. The integrated PESU membrane is pre-wetted and flushed, which saves hours in set-up and validation time, as well as eliminates the costs of using buffers and purified water to prepare the membrane.
Since the Sartocon assemblies are designed with the same hydrodynamic flow path as SSB’s larger production-scale filter devices and all device materials and accessories are manufactured to the same industrial quality-assured specifications, linear scale-up and process transfer is a simple process.
The PESU membrane inside the Sartocon assemblies is available in several sizes and 10-300 KDa molecular weight cut-offs and is robust enough for use in broad pH and temperature ranges. These features combined with the Sartocon assemblies’ single-use design, which prevents product cross-contamination, means they are perfect for use in R&D applications, CMOs and multi-product facilities.
“Following on from the successful introduction in 2015 of the Hydrosart membrane in our single-use Sartocon filter loop assemblies, we made our PESU membrane for these applications available as well. Now customers can select from a broader range of membrane polymers and cut offs for ensuring optimal parameter for their specific process. When compared with reusable filter cassettes, we estimate that using these new single-use, PESU membrane-based assemblies will reduce processing time by around 60% and could save up to 2,000 euro per batch on buffer and water costs,” Frank Meyeroltmanns, expert for crossflow-filtration at SSB explains.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance